Qing Zhai

270 Dong An Road
Shanghai, 200032, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 32 publications

Efficacy and safety of biosimilar trastuzumab (HLX02) in patients with HER2-positive advanced breast cancer: a retrospective real-world analysis.

Efficacy and safety of biosimilar trastuzumab (HLX02) in patients with HER2-positive advanced breast cancer: a retrospective real-world analysis.

Journal: Frontiers in oncology

Published: May 04, 2025

Pharmacological Targeting of DHHC9-Mediated STRN4 Palmitoylation to Suppress YAP-Driven Cancer Metastasis.

Pharmacological Targeting of DHHC9-Mediated STRN4 Palmitoylation to Suppress YAP-Driven Cancer Metastasis.

Journal: Journal of cellular and molecular medicine

Published: February 24, 2025

Comparing the Differences in Adverse Events among Chimeric Antigen Receptor T-Cell Therapies: A Real-World Pharmacovigilance Study.

Comparing the Differences in Adverse Events among Chimeric Antigen Receptor T-Cell Therapies: A Real-World Pharmacovigilance Study.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: July 09, 2024

Assessing the effectiveness and safety of surufatinib versus everolimus or sunitinib in advanced neuroendocrine neoplasms: insights from a real-world, retrospective cohort study using propensity score and inverse probability treatment weighting analysis.

Assessing the effectiveness and safety of surufatinib versus everolimus or sunitinib in advanced neuroendocrine neoplasms: insights from a real-world, retrospective cohort study using propensity score and inverse probability treatment weighting analysis.

Journal: Journal of gastrointestinal oncology

Published: March 25, 2024

CDK4/6 inhibitors in drug-induced liver injury: a pharmacovigilance study of the FAERS database and analysis of the drug-gene interaction network.

CDK4/6 inhibitors in drug-induced liver injury: a pharmacovigilance study of the FAERS database and analysis of the drug-gene interaction network.

Journal: Frontiers in pharmacology

Published: January 29, 2024

Ocular adverse events associated with BRAF and MEK inhibitor combination therapy: a pharmacovigilance disproportionality analysis of the FDA adverse event reporting system.

Ocular adverse events associated with BRAF and MEK inhibitor combination therapy: a pharmacovigilance disproportionality analysis of the FDA adverse event reporting system.

Journal: Expert opinion on drug safety

Published: March 10, 2023

Safety of trastuzumab deruxtecan: A meta-analysis and pharmacovigilance study.

Safety of trastuzumab deruxtecan: A meta-analysis and pharmacovigilance study.

Journal: Journal of clinical pharmacy and therapeutics

Published: August 31, 2022

Impact of individualized pharmaceutical care on efficacy and safety of opioid-tolerant outpatients with cancer pain: a multicenter randomized controlled trial.

Impact of individualized pharmaceutical care on efficacy and safety of opioid-tolerant outpatients with cancer pain: a multicenter randomized controlled trial.

Journal: Annals of translational medicine

Published: August 05, 2022

SKF96365 impedes spinal glutamatergic transmission-mediated neuropathic allodynia.

SKF96365 impedes spinal glutamatergic transmission-mediated neuropathic allodynia.

Journal: The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology

Published: June 08, 2022

Establishment and validation of analytical methods for 15 hazardous drugs by UPLC-Q/Orbitrap-HRMS.

Establishment and validation of analytical methods for 15 hazardous drugs by UPLC-Q/Orbitrap-HRMS.

Journal: Annals of translational medicine

Published: April 18, 2022

Predicting Lapatinib Dose Regimen Using Machine Learning and Deep Learning Techniques Based on a Real-World Study.

Predicting Lapatinib Dose Regimen Using Machine Learning and Deep Learning Techniques Based on a Real-World Study.

Journal: Frontiers in oncology

Published: March 11, 2022

Evolution of drug regulations and regulatory innovation for anticancer drugs in China.

Evolution of drug regulations and regulatory innovation for anticancer drugs in China.

Journal: Acta pharmaceutica Sinica. B

Published: March 06, 2022

Showing 1-12 of 32

Last Updated: 09/26/2026